Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04250558 · ClinicalTrials.gov registry record
ICG Fluorescence Imaging in Lower Extremity Amputation Patients
A clinical trial, sponsored by Dartmouth-Hitchcock Medical Center.
- Completed
- Registry status
- 17
- Enrollment target
NCT04250558: Completed study, sponsored by Dartmouth-Hitchcock Medical Center.
NCT04250558 is a clinical trial that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 17 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04250558 has completed, sponsored by Dartmouth-Hitchcock Medical Center.
- COMPLETED
- Registry status
- 17 participants
- Enrollment target
Study Summary
This is a non-randomized prospective study of 30 patients scheduled to undergo lower extremity amputation (below the knee, through the knee or above the knee) evaluating bone perfusion and viability using indocyanine green (ICG) fluorescence imaging at several steps during surgical procedure.
Primary Outcome
Changes to total bone blood flow changes that occur as a result of osteotomy and soft tissue stripping associated with the amputationas will be assessed by immunofluorescence based dynamic constrast enhanced fluorescence imaging.
Interventions
- PROCEDURE Lower Extremity Amputation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2020-02-01 |
| Est. Completion | 2023-06-30 |
What the finished NCT04250558 record still lists
NCT04250558 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 17 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Lower Extremity Amputation is the first listed.
NCT04250558 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04250558 about?
NCT04250558 is a clinical study titled "ICG Fluorescence Imaging in Lower Extremity Amputation Patients". This is a non-randomized prospective study of 30 patients scheduled to undergo lower extremity amputation (below the knee, through the knee or above the knee) evaluating bone perfusion and viability using indocyanine green (ICG) fluorescence imaging at several steps during surgical procedure.
What is the current status of trial NCT04250558?
This trial is currently completed. The enrollment target is 17 participants. The study started on 2020-02-01. Estimated completion is 2023-06-30.
What interventions are being tested in trial NCT04250558?
The interventions under investigation include: Lower Extremity Amputation (PROCEDURE).
Who is sponsoring clinical trial NCT04250558?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI